CORONA Remedies Reports Strong Q1 FY27 Results, Driving 21.9% Revenue Growth and 30.1% PAT Increase

CORONA Remedies Reports Strong Q1 FY27 Results, Driving 21.9% Revenue Growth and 30.1% PAT Increase​

Ahmedabad | July 31, 2026 – CORONA Remedies Limited, a leading India-focused pharmaceutical company, has announced its unaudited financial results for the first quarter of the fiscal year 2027 (Q1FY27). The company reported robust revenue and resilient margins, attributing the performance to consistent brand building initiatives and enhanced operational efficiencies.

The Q1FY27 results demonstrated significant growth across key metrics. Revenue from Operations stood at ₹422.4 Cr, marking a 21.9% year-on-year (Y-o-Y) increase compared to the previous year. Concurrently, Profit After Tax (PAT) for Q1FY27 reached ₹60.1 Cr, reflecting a strong Y-o-Y growth of 30.1%. The PAT margin stood at 14.2%, which is an improvement of 90 basis points (bps) compared to the previous year.

Financial performance details are summarized below:

Business Milestones and Market Positioning​

The company achieved several key operational and market milestones during the quarter. CORONA Remedies was noted to be one of the fastest growing companies among the top 30 firms in the industry over the last six consecutive months, according to MAT data for June '26, outperforming the market by 1.9 months.

In terms of market ranking, the company advanced three places within a year, reaching the 26th rank nationally from where it stood at 29th rank as of MAT June '25. Furthermore, CORONA established itself in the 5th rank for Gynaecology, highlighting its leadership commitment in this therapy segment.

Operationally, the company inaugurated and initiated the commercialization of its EU-GMP approved Female Hormone Manufacturing Facility based in Ahmedabad on June 30, 2026. The organization also began the smooth integration process of the Wokadine brand from both a supply and distribution perspective.

Management Outlook Focuses on Core Therapies​

Nirav K. Mehta, Managing Director & CEO of CORONA Remedies Limited, commented on the quarter's performance, noting that Q1 FY27 underscores the company’s commitment to consistent growth through operational excellence and brand building.

He stated that the positive outcomes observed are a result of well-implemented strategies. The management aims to maintain a steady focus on core therapies including Women's Healthcare, Cardio-diabetes, Pain Management, and Urology. Additionally, the company is strengthening its presence in the Infertility and Biosimilar segment.

CORONA Remedies Limited was established in 2004 and operates through WHO-GMP/EU GMP certified manufacturing facilities, maintaining strong innovation capabilities through DSIR-approved R&D centers.

CORONA Stock Price Movement​

Today, shares of CORONA Remedies Limited edged higher to close at ₹2098.8, reporting a 0.43% gain in the post-market session. The stock saw 18,140 shares traded, concluding near its highly volatile 52-week trading range.